Moderna y Merck afirman que vacuna contra melanoma reduce riesgo de recaída

Moderna y Merck afirman que vacuna contra melanoma reduce riesgo de recaída

Negocios Salud

Moderna y Merck declararon que su vacuna de ARNm personalizada contra el melanoma, intismeran autogene, redujo el riesgo de recaída o diseminación de la enfermedad en un ensayo fase III con 1 137 pacientes de alto riesgo, cuyos resultados se presentaron en la reunión de la Sociedad Americana de Oncología Clínica en Chicago el 17 de agosto. Informes anteriores de Gizmodo y Ars Technica señalaron que la vacuna, administrada junto con Keytruda de Merck, prolongó la supervivencia libre de recaída y sin metástasis a distancia. Yahoo Finance informó posteriormente que las acciones de Moderna cayeron un 12 % en la negociación previa al mercado tras un aumento previo del 177 % tras el éxito del ensayo.

Actores

Moderna Merck Stéphane Bancel

Ubicaciones

American Society of Clinical Oncology meeting

Artículos

24 de agosto de 2026
1 en total
Inside Moderna and Merck’s cancer vaccine triumph
Inside Moderna and Merck’s cancer vaccine triumph

STAT • 24 de ago 08:35

A phase III study of the mRNA-based melanoma vaccine intismeran autogene showed a statistically significant reduction in the chance of disease recurrence or spread, according to results released by Moderna and Merck.

Credibilidad 72% Manip. 8% Centro
20 de agosto de 2026
2 en total
Moderna and Merck's mRNA Melanoma Vaccine Looks Like a Game Changer
Moderna and Merck's mRNA Melanoma Vaccine Looks Like a Game Changer

Gizmodo • 20 de ago 16:15

A Phase 3 trial showed that adding Moderna's personalized mRNA vaccine to Merck's Keytruda immunotherapy extended recurrence-free survival in high-risk melanoma patients.

Credibilidad 72% Manip. 32% Centro
After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next
After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next

Yahoo Finance • 20 de ago 09:10

Moderna's stock fell 12% in pre-market trading following a 177% jump on news that its mRNA melanoma vaccine met primary endpoints in a Phase 3 trial, prompting mixed reactions from analysts.

Credibilidad 72% Manip. 9% Centro
19 de agosto de 2026
2 en total
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Ars Technica • 19 de ago 16:53

A late-stage study of 1,137 melanoma patients showed that a personalized mRNA vaccine combined with Keytruda extended recurrence-free and distant metastasis-free survival, according to Moderna and Merck.

Credibilidad 78% Manip. 12% Centro
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

NBC News • 19 de ago 14:37

An mRNA-based personalized vaccine combined with Merck's Keytruda showed interim evidence of extending disease-free time for high-risk melanoma patients, according to a company release.

Credibilidad 68% Manip. 12% Centro

Eventos relacionados